congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
Disease Area Tab
PublicationView
Poster
Dato-DXd, T-DXd, Valemetostat
ASCO 2024 | May 31 - June 4, 2024
A phase 1b, multicenter, open-label study of valemetostat in combination with DXd antibody-drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) or datopotamab deruxtecan (Dato-DXd), in patients with solid tumors
Poster
I-DXd
WCLC 2023 | September 9-12, 2023
A phase 2 study of ifinatamab deruxtecan (I-DXd; DS-7300) in patients with previously treated ES-SCLC
Poster
Dato-DXd
WCLC 2023 | September 9-12, 2023
AVANZAR: Phase III study of datopotamab deruxtecan (Dato-DXd) + durvalumab + carboplatin as first-line treatment of advanced/metastatic non-small-cell lung cancer
Poster
T-DXd
ESMO 2023 | October 20-24, 2023
Baseline circulating tumor DNA biomarker analysis of patients with human epidermal growth factor receptor 2 overexpressing metastatic non–small cell lung cancer treated with trastuzumab deruxtecan
Poster
HER3-DXd
WCLC 2023 | September 9-12, 2023
Clinical outcomes of real-world treatment for metastatic EGFRm NSCLC after osimertinib and platinum-based chemotherapy
Poster
Dato-DXd
ESMO 2024 | September 13-17, 2024
Dato-DXd vs docetaxel in patients with advanced nonsquamous non-small cell lung cancer with brain metastases: Results from TROPION-Lung01
Oral
Dato-DXd
WCLC 2023 | September 9-12, 2023
Datopotamab deruxtecan (Dato-DXd) + durvalumab ± carboplatin in advanced/metastatic NSCLC: Initial results from the phase 1b TROPION-Lung04 study
Poster
Dato-DXd
ASCO 2024 | May 31 - June 4, 2024
Datopotamab deruxtecan (Dato-DXd) in Chinese patients with advanced or metastatic non-small cell lung cancer (NSCLC): Results from the phase 1/2 TROPION-PanTumor02 study
Poster
Dato-DXd
ELCC 2024 | March 20-23, 2024
Datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC) – nonsquamous (NSQ) histology in the phase 3 TROPION-Lung01 Trial
Poster
Dato-DXd
ASCO 2024 | May 31 - June 4, 2024
Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab with or without platinum chemotherapy as first-line therapy for advanced non-small cell lung cancer (NSCLC); subgroup analysis from TROPION-Lung02